To review the incidence and risk factors for cytomegalovirus (CMV) infection and disease following renal transplantation, and the use of intravenous acyclovir for infection prophylaxis.
Data Sources
An English-language literature search using MEDLINE (1982–93), Index Medicus (1982–93), and bibliographic reviews of related textbooks and review articles.
Study Selection
One hundred forty-five articles were selected. Articles were assessed for study quality and specific information addressing the stated purpose. In articles reporting the results of clinical trials, emphasis was placed on comparative pharmacokinetic parameters, efficacy, and toxicity.
Synthesis
A review of human trials suggests that acyclovir is effective for prevention of CMV infection and disease following renal transplantation. When compared with active or passive CMV immunization, ganciclovir, and foscamet sodium, acyclovir appears to exhibit the most favorable combination of safety and efficacy in the renal transplant population. However, the optimal dose of intravenous acyclovir when compared with oral administration is not clearly established.
Conclusions
Acyclovir will continue to be widely used for CMV prophylaxis following renal transplantation. Postoperative complications often require the use of intravenous medications, and the optimal dosing schedule for intravenous acyclovir in this population is an issue that needs to be addressed. A randomized, concentration-controlled clinical trial may be the best approach to establish a safe and effective dosing schedule for intravenous acyclovir administration in the renal transplant population.
Get full access to this article
View all access options for this article.
References
1.
RubinRH, Tolkoff-RubinNE.Opportunistic infections in renal allograft recipients.Transplant Proc1988;20(6 suppl 8):12–8.
2.
ZaiaJA.Epidemiology and pathogenesis of cytomegalovirus disease.Semin Hematol1990;27(2 suppl 1):5–10.
3.
DavisCL.The prevention of cytomegalovirus disease in renal transplantation.Am J Kidney Dis1990;16:175–88.
4.
PetersonPK, BalfourHH, MarkerSC, FrydDS, HowardRJ, SimmonsRL.Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation.Medicine1980;59:283–300.
5.
GlennJ.Cytomegalovirus infections following renal transplantation.Rev Infect Dis1981;3:1151–78.
6.
MarkerSC, HowardRJ, SimmonsRL.Cytomegalovirus infection: a quantitative prospective study of three hundred twenty consecutive renal transplants.Surgery1981;89:660–71.
7.
EmanuelD, CunninghamI, Jules-Elysee K, BrochsteinJA, KermanNA, LaverJ, etal.Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin.Ann Intern Med1988;109:777–82.
8.
ReedEC, BowdenRA, DandlikerPS, LillebyKE, MeyersJD.Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants.Ann Intern Med1988;109:783–8.
9.
SchmidtGM, KovacsA, ZaiaJA, HorakDA, BlumeKG, NademaneeAP, etal.Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.Transplantation1988; 46:905–7.
10.
HechtDW, SyndmanDR, CrumpackerCS, WernerBG, Heinze-LaceyB.Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia.J Infect Dis1988;157:187–90.
11.
NicholsonML, FlowerAJE, SimpsonA, DonnellyPK, VeitchPS, BellPREGanciclovir for severe cytomegalovirus infection in transplant recipients. Lancet1988;2:1501–2.
12.
HiesseC, FarquetC, DussaixE, CharpentierB, FriesD.Ganciclovir for cytomegalovirus infection in renal transplant recipients.Lancet1989;1:216–7.
13.
De KoningJ, Van DorpWT, Van EsLA, Van't WoutJW, Van Der WoudeFJ.Ganciclovir effectively treats cytomegalovirus disease after solid-organ transplantation, even during rejection treatment.Nephrol Dial Transplant1992;7:350–6.
14.
RossCN, BeynonHL, SavillJS, WatkinsRP, CohenJ, PuseyCD, etal.Ganciclovir treatment for cytomegalovirus infection in immunocompromised patients with renal disease.Q J Med1991;81:929–36.
15.
BurnsKD, Johnson-Whittaker L, CoutureRA, EidusL, GarberG.Successful treatment of renal allograft rejection in the presence of cytomegalovirus disease. A report of two cases.Am J Nephrol1990; 10:162–6.
16.
ReedEC, WolfordJL, KopeckyKJ, LillebyKE, DandlikerPS, TodaroJL, etal.Ganciclovir for the treatment of cytomegalovirus enteritis in bone marrow transplant patients: a randomized, placebo-controlled trial.Ann Intern Med1990;112:505–10.
17.
HrebinkoR, JordanML, DrummerJS, HickeyDP, ShapiroR, VivasC, etal.Ganciclovir for invasive cytomegalovirus infection in renal allograft recipients.Transplant Proc1991;23(3 suppl 3):1346–7.
18.
MeyersJD.Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients.Transplant Proc1991;23(3 suppl 3):139–43.
19.
DearmondB.Clinical trials of ganciclovir.Transplant Proc1991;23(3 suppl 3):171–3.
20.
Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxy-methyl) guanine in patients with AIDS and other immunodeficiencies. N Engl J Med1986;314:801–5.
21.
SyndmanDR.Ganciclovir therapy for cytomegalovirus disease associated with renal transplants.Rev Infect Dis1988;10(suppl 3):S554–60.
22.
PayaCV, HermansPE, SmithTF, RakelaJ, WiesnerRH, Krom RAF, etal.Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection.Transplantation1988;46: 229–34.
23.
HarbisonMA, DegirolamiPC, JenkinsRL, HammerSM.Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients.Transplantation1988;46:82–8.
24.
MeyersJD.Management of cytomegalovirus infection.Am J Med1988;85(suppl 2A):102–6.
25.
TymsAS, TaylorDL, ParkinJM.Cytomegalovirus and the acquired immunodeficiency syndrome.J Antimicrob Chemother1989;23 (suppl A):89–105.
26.
RingdenO, LonnqvistB, PaulinT, AhlmenJ, KlintmalmG, WahrenB, etal.Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.J Antimicrob Chemother1986;17:373–87.
27.
Le HoangP, GirardB, RobinetM, MarcelP, ZazounL, MatheronS, etal.Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.Ophthalmology1989;96:865–74.
28.
BalfourHH, ChaceBA, StapletonJT, SimmonsRL, FrydDS.A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.N Engl J Med1989;320:1381–7.
29.
FletcherCV, EnglundJA, EdelmanCK, GrossCR, DunnDL, BalfourHH.Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients.Antimicrob Agents Chemother1991;35:938–43.
30.
HoM.Observations from transplantation contributing to the understanding of pathogenesis of CMV infection.Transplant Proc1991;23(3 suppl 3):104–9.
31.
BettsRF.The relationship of epidemiology and treatment factors to infection and allograft survival in renal transplantation.Birth Defects1984;20:87–99.
32.
DrewWL, MintzL, MinerRC, SandsM, KettererB.Prevalence of cytomegalovirus infection in homosexual men.J Infect Dis1981; 143:188–92.
33.
DrewWL.Sexual transmission of CMV and its relationship to Kaposi sarcoma in homosexual men.Birth Defects1984;20:121–9.
34.
BowdenRA, SayersM, FlournoyN, NewtonB, BanajiM, ThomasED, etal.Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.N Engl J Med1986;314:1006–10.
35.
MeyersJD, FlournoyN, ThomasED.Nonbacterial pneumonia after allogeneic transplantation. A review of ten years’ experience.Rev Infect Dis1982;4:1119–32.
36.
ZaiaJA.The biology of human cytomegalovirus infection after bone marrow transplantation.Int J Cell Cloning1986;4(suppl 1):135–54.
37.
HoM. Cytomegalovirus. In: MandellGL, DouglasRG, BennettJE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990:1159–72.
38.
HoM, SuwansirikulS, DowlingJN, YoungbloodLA, ArmstrongJA.The transplanted kidney as a source of cytomegalovirus infection.N Engl J Med1975;293:1109–12.
39.
CenH, BreinigM, AtchisonR, HoM, McKnightJL.Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4.J Virol1991;65:976–80.
40.
ZaiaJA.Pathogenesis of CMV-associated diseases in 1990.Transplant Proc1991;23(3 suppl 3):1–4.
41.
BuhlesWC, MastreBJ, TinkerAJ, StrandV, KoretzSHSyntex Collaborative Ganciclovir Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients.Rev Infect Dis1988;10(suppl 3):S495–506.
42.
SheppDH, DandlikerPS, De Miranda P, BurnetteTC, CederbergDM, KirkLE, etal.Activity of 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia.Ann Intern Med 1985;103:368–73.
43.
CarneyWP, HirschMS.Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions.J Infect Dis1981;144:47–54.
44.
KapasiK, RiceGP.Cytomegalovirus infection of peripheral blood mononuclear cells: effects of interleukin-1 and -2 production and responsiveness.J Virol 1988;62:3603–7.
GrundyJE, SuperM, SwenyP, MoorheadJ, LuiSF, BerryNJ, etal.Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus.Lancet1988;2:132–5.
48.
SyndmanDR, WernerBG, Heinz-Lacey B, BerardiVP, TilneyNL, KirkmanRL, etal.Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.N Engl J Med1987;317:1049–54.
49.
BraymanKL, DafoeDC, SmytheWR, BarkerCF, PerloffLJ, NajiA, etal.Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine.Arch Surg1988;123:1502–8.
50.
SmileyML, WlodaverCG, GrossmanRA, BarkerCF, PerloffLJ, TustinNB.The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation.Transplantation1985;40:157–61.
51.
ChouS.Antibody responses to reinfecting strains of cytomegalovirus in transplant recipients.J Infect Dis1989;160:16–21.
52.
WeirMR, IrwinBC, MatersAW, GenemansG, ShenSY, CharacheP, etal.Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity.Transplantation1987;43:187–93.
53.
WhelchelJD, PassRF, DiethelmAG, WhitleyRJ, AlfordCA.Effect of primary and recurrent cytomegalovirus infections upon graft and patient survival after renal transplantation.Transplantation1979;28: 443–6.
54.
WaltzerWC, ArnoldAN, AnaiseD, HurleyS, RaisbeckA, EgelandsdalB, etal.Impact of cytomegalovirus infection and HLA-matching on outcome of renal transplantation.Transplant Proc1987;19:4077–80.
55.
GrundyJE, SuperM, GriffithsPD.Reinfection of a seropositive allograft recipient by cytomegalovirus from donor kidney.Lancet1986;1:159–60.
56.
GrundyJE, SuperM, LuiS, SwenyP, GriffithsPD.The source of cytomegalovirus infection in seropositive renal allograft recipients is frequently the donor kidney.Transplant Proc1987;19:2126–8.
57.
ShackletonCR, KeownPA, LandsbergDN, McCarthyJM, ScudamoreCH, KaneLM, etal.The impact of donor/recipient matching for cytomegalovirus compatibility or identity on the incidence of disease and outcome following renal transplantation.Transplant Proc1991; 23:1350–1.
58.
JeffriesDJ.The spectrum of cytomegalovirus infection and its management.J Antimicrob Chemother1989;23(suppl E):1–10.
59.
QuinnanGV, KirmaniN, RookAH, ManischewitzJF, JacksonL, MoreschiG, etal.Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus in bone marrow transplant recipients.N Engl J Med1982;307:6–13.
60.
RookAH.Interactions of cytomegalovirus with the human immune system.Rev Infect Dis1988;10(suppl 3):460–7.
61.
SimmonsRS, MatasAJ, RattazziLC, BalfourHH, HowardRJ, NajarianJS.Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation.Surgery1977;82:537–46.
62.
WinstonDJ, PollardRB, HoWG, GallagherJG, RasmussenLE, Huang SNY, etal.Cytomegalovirus immune plasma in bone marrow transplant recipients.Ann Intern Med1982;97:11–8.
63.
YeagerAS, GrumetFC, HafleighEB, ArvinAM, BradleyJS, ProberCG.Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.J Pediatrics1981;98:281–7.
64.
GehrzRC, Liu YNC, EckhardtJ, KlausA.Relevance of immune responses to pathogenesis of cytomegalovirus-associated diseases.Transplant Proc1991;23(3 suppl 3):75–84.
65.
ReddenhaseMJ, KeilGM, KoszinowskiUH.The cytotoxic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors.Eur J Immunol1984;15:56–61.
66.
BorysiewiczLK, GrahamS, HicklingJK, MasonPD, SissonsJG.Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity.Eur J Immunol1988;18:269–75.
67.
RinaldoCR, CarneyWP, RichterBS, BlackPH, HirschMS.Mechanisms of immunosuppression in cytomegaloviral mononucleosis.J Infect Dis1980;141:488–95.
68.
HirschMS, SchooleyRT, CosimiAB, RussellPS, DelmonicoFL, Tolkoff-Rubin NE, etal.Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients.N Engl J Med1983;308:1489–93.
69.
BiaM, AndimanW, GaudioK, KligerA, SiegelN, SmithD, etal.Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation.Transplantation1985;40:610–4.
70.
LewisRM, JohnsonPC, GoldenD, Van Buren CT, KermanRH, KahanBD.The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.Transplantation1988;45:353–9.
71.
HoM.Virus infections after transplantation in man.Arch Virol1977;55:1–24.
PassRF, ReynoldsDW, WhelchelJD, DiethelmAG, AlfordCA.Impaired lymphocyte transformation response to cytomegalovirus and phytohemagglutinin in recipients of renal transplants: association with antithymocyte globulin.J Infect Dis1981;143:259–65.
74.
SchooleyRT, HirschMS, ColvinRB, CosimiAB, Tolkoff-Rubin NE, McCluskeyRT, etal.Association of herpes virus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation.N Engl J Med1983;308:307–13.
75.
ChouS, NormanDJ.Effect of OKT3 antibody therapy on cytomegalovirus reactivation in renal transplant recipients.Transplant Proc1985;17:2755–6.
76.
KatzensteinDA, CraneRT, JordanMC.Successful treatment of murine cytomegalovirus disease does not prevent latent virus infection.J Lab Clin Med1986;108:155–60.
77.
ThistlewaiteJR, StuartJK, MayesJT, GaberAO, WoodleS, BuckinghamMR, etal.Complications and monitoring of OKT3 therapy.Am J Kidney Dis1988;11:112–9.
78.
MayesJT, ThistlewaiteJR, StuartJK, BuckinghamMR, StuartFP.Reexposure to OKT3 in renal allograft recipients.Transplantation1988;45:349–53.
79.
KokadoY, TakaharaS, IshibashiM, TanakaK, BabaK, YabuuchiM, etal.Cytomegalovirus infection after renal transplantation: effect of prophylactic hyperimmunoglobulin.Clin Transplantation1989;3:223–7.
80.
RubinRH, Tolkoff-RubinNE.Infection: the new problems.Transplant Proc1989;21:1440–5.
81.
WittekAE, RookAH, ManischewitzJF, MitchellCD, SmithWJ, BurdickJF, etal.Reduced risk and severity of cytomegalovirus infection in renal allograft recipients treated with cyclosporine (abstract).Clin Res 1986;34:539A.
82.
MetselaarHJ, WeimarWCytomegalovirus infection and renal transplantation.J Antimicrob Chemother1989;23(suppl E):37–47.
83.
Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med1986;314:1219–25.
84.
NajarianJS, FrydDS, StrandM, CanafaxDM, AsherNL, PayneWD, etal.A single institution, randomized, prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.Ann Surg1985;201:142–57.
85.
PetersonPK, RynasiewicsJJ, SimmonsRL, FergusonRM.Decreased incidence of overt cytomegalovirus disease in renal allograft recipients receiving cyclosporine A.Transplant Proc1983;15:457–9.
86.
AckermanJR, LeforWM, WeinsteinS, KahanaL, ShiresDL, TardifG, etal.Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients.Transplant Proc1988;20(suppl 1):469–71.
87.
WhiteNH, YowMD, DemmlerGJ, NortonHJ, HoyleJ, PinckardK, etal.Prevalence of cytomegalovirus antibody in subjects between the ages of 6 and 22 years.J Infect Dis1989;159:1013–7.
88.
ArndtR, NeuserA, DittmerR, HarfmannP, TenschertW, Meyer-Moldenhauer WH, etal.Importance of cytomegalovirus infection in renal transplantation: comparison of DNA in situ hybridization and early antigen detection and virus-specific antibodies as diagnostic tools.Transplant Proc1991;23:1348–9.
89.
BowdenRA.Cytomegalovirus infections in transplant patients: methods of prevention of primary cytomegalovirus.Transplant Proc1991;23(3 suppl):136–8.
90.
BowdenRA, MeyersJD.Prophylaxis of cytomegalovirus infection.Semin Hematol1990;27(suppl 1):17–21.
91.
PlotkinSA, FriedmanHM, FleisherGR, DafoeDC, GrossmanRA, Lynn Smiley M, etal.Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.Lancet1984;1:528–30.
PlotkinSA, StarrSE, FriedmanHM, BraymanK, HarrisS, JacksonS, etal.Effect of Towne live vaccine on cytomegalovirus disease in patients receiving renal transplants: a controlled trial.Ann Intern Med1990;114:525–31.
94.
SimmonsRL, MiglioriRJ.Infection prophylaxis after successful organ transplantation.Transplant Proc1988;20(6 suppl 8):7–11.
95.
BalfourHH.Options for prevention of cytomegalovirus disease.Ann Intern Med1991;114:598–9.
96.
SyndmanDR, McIverJ, LeszczynskiJ, ChoSI, WernerBG, BerardiVP, etal.A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients.Transplantation1984;38:553–7.
97.
DreikornK, DoerrHW, GeursenRG.Cytomegalovirus (CMV) infections in renal transplant recipients. Preliminary results of prophylaxis by an intramuscular human hyperimmune CMV Ig.Scand J Urol Nephrol1985;92(suppl):15–21.
98.
FassbinderW, BechsteinPB, ScheuermannEH, SchoeppeW.Incidence of cytomegalovirus-infection after renal transplantation and first experiences with prophylactic hyperimmunoglobulin.Scand J Urol Nephrol1985;92(suppl):23–8.
99.
GregerB, VallbrachtA, KurthJ, SchareckWD, MullerGH, HoptUT, etal.The clinical value of CMV prophylaxis by CMV hyperimmune serum in the kidney transplant patient.Transplant Proc1986;18: 1387–9.
100.
FassbinderW, ErnstW, HankeP, BechsteinPB, ScheuermannEH, SchoeppeW.Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin.Transplant Proc1986;18:1393–6.
101.
SyndmanDR, WernerBG, TilneyNL, KirkmanRL, MilfordEL, ChoSI, etal.A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and open-label trial.Transplant Proc1988;20:24–30.
102.
WeimarW, KramerP, BijnenAB, JeekelJ, RothbarthPH, MasurelN.The incidence of cytomegalo- and herpes simplex virus infections in renal allograft recipients treated with high dose recombinant leucocyte interferon. A controlled study.Scand J Urol Nephrol1985; 92(suppl):37–9.
103.
HimmelsteinDU, WollhandlerS.Interferon for prevention of cytomegalovirus reactivation in renal-transplant recipients (letter).N Engl J Med1983;309:1193.
104.
KramerP, Ten Kate FJW, BijnenAB, JeekelJ, WeimarW.The pathology of interferon-induced renal allograft lesions.Transplant Proc1985;17:58–60.
105.
BalfourHH.Management of cytomegalovirus disease with antiviral drugs.Rev Infect Dis1990;12(suppl 7):S849–60.
106.
BironKK, StanatSC, SorrellJB, FyfeJA, KellerPM, LambeCU, etal.Metabolic activation of the nucleoside analogue-9-([2-hydroxy-1-{hydroxymethyl}ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus.Proc Natl Acad Sci USA1985;82:2473–7.
107.
BalfourHH. Acyclovir. In: PetersonPK, VerhoefJ, eds. The antimicrobial agents annual. 3rd ed. New York: Elsevier Science Publications, 1988:345–60.
108.
PlotkinSA, DrewWL, FelsensteinD, HirschMS.Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine.J Infect Dis1985;152:833–4.
109.
ColeNL, BalfourHH.In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir.Diagn Microbiol Infect Dis1987;6:255–61.
110.
BironKK, FyfeJA, StanatSC, LeslieLK, SorrellJB, LambeCU, etal.A human cytomegalovirus mutant resistant to the nucleoside analog 9([2-hydroxy-1-{hydroxymethyl}ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate.Proc Natl Acad Sci USA1986;83:8769–73.
111.
EriceA, JordanMC, ChaceBA, FletcherC, ChinnockBJ, BalfourHH.Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.JAMA1987;257:3082–7.
112.
CrumpackerC, MarloweS, ZhangJL, AbramsS, WatkinsPGanciclovir Bone Marrow Transplant Treatment Group. Treatment of cytomegalovirus pneumonia.Rev Infect Dis1988;10(suppl 3):S538–46.
113.
EriceA, ChouS, BironKK, StanatSC, BalfourHH, JordanMC.Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients.N Engl J Med1989;320:289–93.
114.
SommadossiJP, CarlisleR.Toxicity of 3’ azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.Antimicrob Agents Chemother1987;31:452–4.
115.
PlotkinSA, StarrSE, BryanCK.In vitro and in vivo responses of cytomegalovirus to acyclovir.Am J Med1982;73(suppl 1A):257–61.
116.
FletcherCV, BalfourHHJr.Evaluation of ganciclovir for cytomegalovirus disease.Drug Intell Clin Pharm1989;23:5–12.
117.
JacobsonMA, CroweS, LevyJ, AweekaF, GambertoglioJ, McManusNEffect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.J Infect Dis1988;158: 862–5.
118.
ApperlyJF, MarcusRE, GoldmanJM, WardleDG, GravettPJ, ChanasA.Foscarnet for cytomegalovirus pneumonitis (letter).Lancet1985;1:1151.
119.
RingdenO, WilczekH, LonnqvistB, GahrtonG, WahrenB, LernestedtJO.Foscarnet for cytomegalovirus infections.Lancet1985;1:1503–4.
120.
KlintmalmG, LonnqvistB, ObergB, GahrtonG, LernestedtJO, LundgrenG, etal.Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.Scand J Infect Dis1985; 17:157–63.
121.
MinorJR, BaltzJK.Foscarnet sodium.DICP Ann Pharmacother1991;25:41–7.
122.
DerayG, CacoubP, Le Hoang P, BaumelouA, SoubrieC, RousselieF, etal.Foscarnet-induced acute renal failure and effectiveness of hemodialysis (letter).Lancet1987;2:216.
123.
CacoubP, DerayG, BaumelouA, Le Hoang P, RozenbaumW, GentiliniM, etal.Acute renal failure induced by foscarnet: 4 cases.Clin Nephrol1989;29:315–8.
124.
MeyersJD.Prevention and treatment of cytomegalovirus infection.Ann Rev Med1991;42:179–87.
125.
WadeJC, McGuffinRW, SpringmeyerSC, NewtonB, SingerJW, MeyersJD.Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon.J Infect Dis1983;148:557–62.
126.
MeyersJD, ReedEC, SheppDH, ThornquistM, DandlikerPS, VicaryCA.Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.N Engl J Med1988; 318:70–5.
127.
WadeJC, HintzM, McGuffinRW, SpringmeyerSC, ConnorJD, MeyersJD.Treatment of cytomegalovirus pneumonia with high-dose acyclovir.Am J Med1982;73(suppl 1A):249–56.
128.
FletcherCV, EnglundJA, BeanB, ChinnockB, BrundageDM, BalfourHH.Continuous infusion of high-dose acyclovir for serious herpesvirus infections.Antimicrob Agents Chemother1989;33:1375–8.
129.
SelbyPJ, PowlesRL, EastonD, PerrenTJ, StolleK, JamesonB, etal.The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.Br J Cancer1989;59:434–8.
130.
HuffJC, BeanB, BalfourHH, LaskinOL, ConnorJD, CoreyL, etal.Therapy of herpes zoster with oral acyclovir.Am J Med1988;85 (suppl 2A):84–9.
131.
BrigdenD, RoslingAE, WoodsNC.Renal function after acyclovir intravenous injection.Am J Med1982;73(suppl 1A):182–5.
132.
KeeneyRE, KirkLE, BridgenD.Acyclovir tolerance in humans.Am J Med1982;73(suppl 1A):176–81.
133.
VartianCV, ShalesDM.Intravenous acyclovir and neurologic effects (letter).Ann Intern Med1983;99:568.
134.
AuwerxJ, KnockaertD, HofkensP.Acyclovir and neurologic manifestations.Ann Intern Med1983;99:882–3.
135.
TomsonCR, GoodshipTH, RodgerRSC.Psychiatric side-effects of acyclovir in patients with chronic renal failure.Lancet1985; 2:385–6.
136.
WadeJC, MeyersJD.Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation.Ann Intern Med1983;98:921–5.
137.
BatailleP, DevosP, NoelJL, DautrevauxC, LokiecF.Psychiatric side-effects with acyclovir (letter).Lancet1985;2:724.
138.
SirotaP, StalerM, MeshulamB.Major depression with psychotic features associated with acyclovir therapy.Drug Intell Clin Pharm1988; 22:306–8.
139.
BeanB, AeppliD.Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster.J Infect Dis1985;151:362–5.
140.
De MirandaP, WhitleyRJ, BlumMR, KeeneyRE, BartonN, CocchettoDM, etal.Acyclovir kinetics after intravenous infusion.Clin Pharmacol Ther1979;26:718–28.
141.
BridgenD, ByeA, FowleASE.Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection.J Antimicrob Chemother1981;7:399–404.
142.
BlumMR, LiaoSHT, De MirandaP.Overview of acyclovir pharmacokinetic disposition in adults and children.Am J Med1982;73(suppl 1A):186–92.
143.
WhitleyRJ, BlumMR, BartonN, De MirandaP.Pharmacokinetics of acyclovir in humans following intravenous administration.Am J Med1982;73(suppl 1A):165–71.
144.
LaskinOL, LongstrethJA, WheltonA, KrasnyHC, KeeneyRC, RoccoL, etal.Effect of renal failure on the pharmacokinetics of acyclovir.Am J Med1982;73(suppl 1A):197–201.
145.
DeMiranda P, BlumMR.Pharmacokinetics of acyclovir after intravenous and oral administration.J Antimicrob Chemother1983; 12(suppl B):29–37.
